Recursion Pharmaceuticals is maintained at a "Hold" rating, pending further regulatory clarity and late-stage trial ...
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) snapped a three-day winning streak on Thursday, surging as much as 17.9 percent ...
The option triggered a $10 million milestone payment to Recursion, bringing total upfront and milestone payments received from Sanofi under the collaboration to $144 million; Recursion is eligible for ...
Recursion (RXRX) lost more than 4% in the early premarket trading on Thursday after a $200M equity offering from the AI-driven drug discovery firm overshadowed a decision by Sanofi (SNY) to select its ...
Asianet Newsable on MSN
RXRX stock heads for its best day in over a year – what’s driving the rally today?
Sanofi selected its first drug development candidate under its collaboration with Recursion.
Recursion Pharmaceuticals stock gained nearly 15% on Thursday thanks to a drug candidate update and milestone payment.
Recursion Pharma launches a $200M equity offering and reports a Sanofi milestone but is rated a Hold on limited near-term ...
Recursion Pharmaceuticals (RXRX) held about $557 million in cash at the end of its second quarter of 2026. Investors should ...
Recursion Pharmaceuticals Inc. announced Thursday that Sanofi has selected the first development candidate under their research collaboration, triggering a $10 million milestone p ...
Recursion Pharmaceuticals, Inc. announced that Sanofi has optioned the first development candidate from the two companies? multi-program research collaboration. The option triggered a $10 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results